Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Genentech |
---|---|
Information provided by: | Genentech |
ClinicalTrials.gov Identifier: | NCT00388206 |
This is an observational study designed to follow patients with metastatic or locally advanced and unresectable CRC, locally advanced or metastatic NSCLC (excluding predominant squamous histology) who are receiving Avastin in combination with first-line chemotherapy. Second-line metastatic CRC patients are also eligible. Patients who started their Avastin containing therapy <3 months prior to enrollment are eligible.
Study Type: | Observational |
Study Design: | Cohort, Prospective |
Official Title: | An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy for Treatment of Metastatic or Locally Advanced and Unresectable Colorectal Cancer and Locally Advanced or Metastatic Non-Small Cell Lung (Excluding Predominant Squamous Cell Histology) |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: The AIRES Call Center | 866-903-4465 | ariesregistry@wilm.ppd.com |
Study Director: | Mary Sugrue, M.D. | Genentech |
Responsible Party: | Genentech, Inc. |
Study ID Numbers: | AVF3991n |
Study First Received: | October 12, 2006 |
Last Updated: | March 20, 2008 |
ClinicalTrials.gov Identifier: | NCT00388206 |
Health Authority: | United States: Institutional Review Board |
NSCLC Avastin anti-VEGF lung cancer |
colorectal cancer ARIES Colon Cancer |
Thoracic Neoplasms Non-small cell lung cancer Digestive System Neoplasms Gastrointestinal Diseases Colonic Diseases Bevacizumab Intestinal Diseases Rectal Diseases Intestinal Neoplasms |
Carcinoma Digestive System Diseases Respiratory Tract Diseases Lung Neoplasms Lung Diseases Gastrointestinal Neoplasms Carcinoma, Non-Small-Cell Lung Colorectal Neoplasms Neoplasms, Glandular and Epithelial |
Respiratory Tract Neoplasms Neoplasms Neoplasms by Site Neoplasms by Histologic Type |